The effects of piroxicam and deracoxib on canine mammary tumour cell line

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Üstün Alkan, Fulya ^a   Üstüner, Oya ^a   Bakirel, Tülay ^a   Çinar, Suzan ^b   Erten, Gaye ^b   Deniz, Günnur ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DERACOXIB; PIROXICAM; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONAMIDE;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; NONHUMAN; ANIMAL; CELL SURVIVAL; DOG; DOSE RESPONSE; EXPERIMENTAL NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MAMMARY NEOPLASMS, ANIMAL; PIROXICAM; SULFONAMIDES;

EID: 84871848569     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/976740     Document Type: Article

References (34)

1. Sorenmo K., Canine mammary gland tumors. Veterinary Clinics of North America 2003 33 3 573 596 2-s2.0-0038756389 10.1016/S0195-5616(03)00020-2 (Pubitemid 36798638)
2. Pang L. Y., Cervantes-Arias A., Else R. W., Argyle D. J., Canine mammary cancer stem cells are radio- and chemo-resistant and exhibit an epithelial-mesenchymal transition phenotype. Cancers 2011 3 2 1744 1762 2-s2.0-79959702722 10.3390/cancers3021744
3. Novosad C. A., Principles of treatment for mammary gland tumors. Clinical Techniques in Small Animal Practice 2003 18 2 107 109 2-s2.0-0038600764 10.1053/svms.2003.36625 (Pubitemid 40361692)
4. Ioan Baba A., Câtoi C., Comparative Oncology 2007 Bucharest, Romania The Publishing House of the Romanian Academy
5. Steele V. E., Hawk E. T., Viner J. L., Lubet R. A., Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutation Research 2003 523-524 137 144 2-s2.0-0037295004 10.1016/S0027-5107(02)00329-9 (Pubitemid 36293240)
6. Cheong E., Ivory K., Doleman J., Parker M. L., Rhodes M., Johnson I. T., Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 2004 25 10 1945 1952 2-s2.0-6444232693 10.1093/carcin/bgh184 (Pubitemid 39405914)
7. Farivar-Mohseni H., Kandzari S. J., Zaslau S., Riggs D. R., Jackson B. J., McFadden D. W., Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. American Journal of Surgery 2004 188 5 505 510 2-s2.0-8544284811 10.1016/j.amjsurg.2004.07.025 (Pubitemid 39491094)
8. Doré M., Cyclooxygenase-2 expression in animal cancers. Veterinary Pathology 2011 48 1 254 265 2-s2.0-79951934796 10.1177/0300985810379434
9. Williams C. S., Mann M., DuBois R. N., The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999 18 55 7908 7916 2-s2.0-0033590207 (Pubitemid 30066236)
10. Singh B., Cook K. R., Vincent L., Hall C. S., Berry J. A., Multani A. S., Lucci A., Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. Journal of Surgical Research 2008 147 2 240 246 2-s2.0-43549118879 10.1016/j.jss.2008.02.026
11. Sandler A. B., Dubinett S. M., COX-2 inhibition and lung cancer. Seminars in Oncology 2004 31 7 45 52 2-s2.0-3042836326 10.1053/j.seminoncol.2004.03.045 (Pubitemid 38879414)
12. Chiu L. C. M., Tong K. F., Ooi V. E. C., Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomedicine & Pharmacotherapy 2005 59 supplement 2 S293 S297 2-s2.0-33644537417 10.1016/S0753-3322(05)80049-6
13. Qin J., Yuan J., Li L., Liu H., Qin R., Qin W., Chen B., Wang H., Wu K., In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomedicine & Pharmacotherapy 2009 63 3 241 248 2-s2.0-61349185227 10.1016/j.biopha.2008.04.007
14. Sonzogni-Desautels K., Knapp D. W., Sartin E., Doré M., Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours. Veterinary and Comparative Oncology 2011 9 3 161 171 10.1111/j.1476-5829.2010. 00242.x
15. Grösch S., Maier T. J., Schiffmann S., Geisslinger G., Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute 2006 98 11 736 747 2-s2.0-33745238704 10.1093/jnci/djj206 (Pubitemid 43983297)
16. Zhang H., Ye Y., Bai Z., Wang S., The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway. Digestive Diseases and Sciences 2008 53 8 2195 2203 2-s2.0-46449090624 10.1007/s10620-007-0139-0
17. Mohammed S. I., Bennett P. F., Craig B. A., Glickman N. W., Mutsaers A. J., Snyder P. W., Widmer W. R., DeGortari A. E., Bonney P. L., Knapp D. W., Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Research 2002 62 2 356 358 2-s2.0-0037081169 (Pubitemid 34106402)
18. Souza C. H., Toledo-Piza E., Amorin R., Barboza A., Tobias K. M., Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Canadian Veterinary Journal 2009 50 5 506 510 2-s2.0-67650116221
19. Schmidt B. R., Glickman N. W., DeNicola D. B., De Gortari A. E., Knapp D. W., Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 2001 218 11 1783 1786 2-s2.0-0035369145 (Pubitemid 32520131)
20. Royals S. R., Farese J. P., Milner R. J., Lee-Ambrose L., van Gilder J., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. American Journal of Veterinary Research 2005 66 11 1961 1967 2-s2.0-30744459597 10.2460/ajvr.2005.66.1961 (Pubitemid 43091720)
21. Knottenbelt C., Chambers G., Gault E., Argyle D. J., The in vitro effects of piroxicam and meloxicam on canine cell lines. Journal of Small Animal Practice 2006 47 1 14 20 2-s2.0-33645139598 10.1111/j.1748-5827.2006.00006.x
22. Cox S. K., Roark J., Gassel A., Tobias K., Determination of deracoxib in feline plasma samples using high performance liquid chromatography. Journal of Chromatography B 2005 819 1 181 184 2-s2.0-22844444722 10.1016/j.jchromb.2005. 01.025 (Pubitemid 41583178)
23. Hellmén E., Canine mammary tumour cell lines established in vitro. Journal of Reproduction and Fertility 1993 47 489 499 2-s2.0-0027350713
24. Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 1983 65 1-2 55 63 2-s2.0-0021061819 (Pubitemid 14203433)
25. van Engeland M., Nieland L. J. W., Ramaekers F. C. S., Schutte B., Reutelingsperger C. P. M., Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998 31 1 1 9 (Pubitemid 28050057)
26. Knapp D. W., Chan T. C. K., Kuczek T., Reagan W. J., Park B., Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. American Journal of Veterinary Research 1995 56 6 801 805 2-s2.0-0029066652
27. Wolfesberger B., Walter I., Hoelzl C., Thalhammer J. G., Egerbacher M., Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Research in Veterinary Science 2006 80 3 308 316 2-s2.0-32044447935 10.1016/j.rvsc.2005.07.013 (Pubitemid 43192713)
28. McFadden D. W., Riggs D. R., Jackson B. J., Cunningham C., Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. International Journal of Oncology 2006 29 4 1019 1023 2-s2.0-34250218734
29. Moore B. C., Simmons D. L., COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. Current Medicinal Chemistry 2000 7 11 1131 1144 2-s2.0-0033759331
30. Rao C. V., Reddy B. S., NSAIDs and chemoprevention. Current Cancer Drug Targets 2004 4 1 29 42 2-s2.0-1542409978 10.2174/1568009043481632 (Pubitemid 38332562)
31. Basu A., Haldar S., The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Molecular Human Reproduction 1998 4 12 1099 1109 2-s2.0-0031593748 (Pubitemid 28552792)
32. Krol M., Pawlowski K. M., Skierski J., Rao N. A. S., Hellmen E., Mol J. A., Motyl T., Transcriptomic profile of two canine mammary cancer cell lines with different proliferative and anti-apoptotic potential. Journal of Physiology and Pharmacology 2009 60 1 95 106 2-s2.0-67749101213
33. Grösch S., Tegeder I., Niederberger E., Bräutigam L., Geisslinger G., COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. The Journal of the Federation of American Societies for Experimental Biology 2001 15 14 2742 2744 2-s2.0-0035650943
34. Ding H., Han C., Gibson-D'Ambrosio R., Steele V. E., D'Ambrosio S. M., Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1. International Journal of Cancer 2003 107 5 830 836 2-s2.0-0242332090 10.1002/ijc.11499 (Pubitemid 37339739)